

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**RAJYA SABHA
UNSTARRED QUESTION NO. 280
ANSWERED ON 4TH FEBRUARY, 2025**

CASES OF CERVICAL AND BREAST CANCER AMONG WOMEN

280. DR. LAXMIKANT BAJPAYEE:

Will the MINISTER OF **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether the cases of cervical and breast cancer among women have increased during the last few years, if so, the reasons therefor and the number of such cases in the country during the last five years, State-wise;
- (b) whether most of the drugs available for treatment of such cancers are patented and costly, if so, the details of generic drugs available for treatment; and
- (c) the measures being taken by Government to facilitate patients with regard to treatment, to provide medicines at reasonable prices and to educate them for prevention in an appropriate manner?

ANSWER

**THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE
(SHRI PRATAPRAO JADHAV)**

(a) As per the Indian Council of Medical Research (ICMR) - National Cancer Registry Programme (ICMR-NCRP) Data, under the Ministry of Health & Family Welfare, the estimated number of incidence of cervical and breast cancer cases during the last five years are increasing in the country. State/UT wise list is enclosed in attached Annexure-I and Annexure-II.

The increase in cancer cases could be due to : (i) Cancer is known to be a disease that increases in incidence with increasing age; (ii) Control of communicable diseases has increased life expectancy and therefore more population being exposed towards the development of cancer; (iii) The increase in population due to growth also contributes to the increase in the number of cancer cases; (iv) Improved literacy, greater consciousness about health in general and cancer in particular makes more and more people seek medical advice at an earlier stage and (v) Availability of sophisticated and improved diagnostic techniques aid in detection of tumors that would have been missed at earlier times.

(b) & (c) The Government ensures that the scheduled drugs for cancer are not sold above their ceiling price fixed by NPPA and non- scheduled drugs do not avail increase in Maximum Retail Price (MRP) beyond 10 percent in preceding 12 months. DPCO, 2013 provides for deposition of overcharge amount by the manufacturers in case of default in implementing the provisions of this Order.

The Department of Revenue, Ministry of Finance has reduced the Customs Duty to Nil and GST rates

from 12% to 5% for the three anticancer drugs namely, Trastuzumab Deruxtecan, Osimertinib, and Durvalumab vide Notification 30/2024 dated 23.07.2024 {Sr. No III (iv)} and Notification no. 05/2024 dated 08.10.2024, respectively. Accordingly, NPPA issued OM dated 28.10.2024 directing companies to reduce MRP on account of reduction in GST rates and exemption from Custom Duties to pass on the benefit of reduced taxes and duties to consumer.

Under Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), quality medicine at affordable prices is offered to people. The prices of Jan Aushadhi medicines are cheaper by at least 50%, and in some cases, by 80% to 90% of the market price of branded medicines available in the market. 83 products for cancer treatment have been brought under the basket of drugs offered by Jan AushadhiKendras. The list of 83 products is at Annexure III.

Cancer is diagnosed and treated at various levels in the health care delivery system including District Hospitals, Medical Colleges, Central Institutes like AIIMS and private sector hospitals. The treatment in Government Hospitals is either free or highly subsidized for the poor and needy.

Under Pradhan Mantri Jan Arogya Yojana (PMJAY), health assurance/ insurance cover of Rs. 5 lakhs per family per year for secondary or tertiary care hospitalization to over 55 Crores beneficiaries is provided. The treatment packages under AB-PMJAY are very comprehensive covering various treatment related aspects such as drugs and diagnostic services.

Affordable Medicines and Reliable Implants for Treatment (AMRIT) Pharmacy stores have been set up in some hospitals/institutions, with an objective to make available drugs including drugs for cancer at a substantial discount vis-à-vis the MRP.

Table 1: Estimated Incidence of Cervical cancer cases in India by different State/UT (2019-2023)					
State	2019	2020	2021	2022	2023
Andaman & Nicobar Islands	21	23	23	25	25
Andhra pradesh	3713	3799	3886	3973	4063
Arunachal pradesh	68	71	74	75	78
Assam	1754	1802	1851	1900	1952
Bihar	4941	5073	5207	5348	5489
Chandigarh	58	58	60	62	63
Chattisgarh	1467	1507	1545	1584	1626
Dadra & Nagar Haveli	15	15	15	16	17
Daman	9	9	9	10	12
Delhi	1217	1259	1303	1348	1394
Goa	101	104	106	107	109
Gujarat	3637	3738	3840	3943	4048
Haryana	1486	1536	1580	1630	1678
Himachal pradesh	461	474	483	495	506
Jammu & Kashmir UT	612	632	648	666	684
Jharkhand	1723	1770	1821	1874	1926
Karnataka	4419	4536	4657	4776	4900
Kerala	1699	1734	1771	1804	1840
Ladakh UT	15	16	16	16	17
Lakshadweep	4	4	4	4	6
Madhya pradesh	3934	4042	4151	4264	4378
Maharashtra	6545	6708	6872	7037	7207
Manipur	101	103	107	112	117
Meghalaya	109	111	113	117	123
Mizoram	134	139	143	147	153
Nagaland	114	116	121	124	127
Orissa	2595	2656	2717	2778	2844
Pondicherry	128	133	138	143	148
Punjab	2223	2280	2339	2399	2459
Rajasthan	3620	3721	3822	3927	4034
Sikkim	26	26	27	29	29
Tamil nadu	7768	7958	8144	8337	8534
Telangana	2466	2532	2595	2665	2731
Tripura	185	191	194	199	204
Uttar pradesh	9793	10046	10301	10559	10825
Uttaranchal	594	608	624	639	656
West bengal	5534	5679	5823	5971	6119
Total	73289	75209	77130	79103	81121

Ref: National Cancer Registry Programme report, 2020

Table 2: Estimated Incidence of Cervical cancer cases in India by different State/UT - (2014-2023) - Females

State	2019	2020	2021	2022	2023
Andaman & Nicobar Islands	25	26	26	28	28
Andhra pradesh	4066	4157	4249	4341	4435
Arunachal pradesh	26	26	27	28	28
Assam	1044	1071	1100	1128	1157
Bihar	5214	5352	5493	5638	5786
Chandigarh	60	62	64	65	67
Chattisgarh	1549	1590	1630	1673	1717
Dadra & Nagar Haveli	15	16	17	18	19
Daman	11	12	12	12	12
Delhi	1255	1299	1343	1389	1436
Goa	102	103	106	109	110
Gujarat	3850	3955	4062	4170	4280
Haryana	1572	1620	1669	1720	1771
Himachal pradesh	487	499	511	523	535
Jammu & Kashmir UT	656	674	694	712	732
Jharkhand	1815	1866	1920	1972	2027
Karnataka	4868	4995	5124	5255	5388
Kerala	3058	3118	3179	3240	3301
Ladakh UT	13	14	14	15	15
Lakshadweep	5	5	5	5	5
Madhya pradesh	4166	4278	4395	4514	4634
Maharashtra	6598	6761	6926	7094	7265
Manipur	61	63	65	68	71
Meghalaya	33	33	34	35	36
Mizoram	45	45	47	48	50
Nagaland	31	32	33	33	35
Orissa	2730	2793	2857	2923	2989
Pondicherry	107	110	115	119	124
Punjab	2246	2303	2361	2421	2480
Rajasthan	3836	3942	4051	4162	4274
Sikkim	12	12	13	13	13
Tamil nadu	5301	5453	5607	5765	5926
Telangana	2716	2787	2857	2928	3001
Tripura	60	62	64	65	67
Uttar pradesh	10365	10629	10898	11172	11451
Uttaranchal	624	641	658	674	692
West bengal	5859	6010	6161	6315	6472
India	74481	76414	78387	80390	82429

Ref: National Cancer Registry Programme report, 2020

**Projected mortality cases for India were computed by applying Mumbai Mortality/Incidence (MI) ratio to the projected incidence cancer cases.

Annexure-III

Sl. No.	Name of the Medicine/Product	Unit
1	Bleomycin Injection IP 15 IU	Vial
2	Cisplatin Injection IP 10 mg per10ml	Vial
3	Cisplatin Injection BP 50mg/50ml	Vial
4	Doxorubicin Injection IP 50mg (2mg per ml)	Vial
5	Etoposide Injection IP 100 mg per 5 ml	Vial
6	Gemcitabine 1000 mg Injection IP	Vial
7	Gemcitabine Injection IP 200mg	Vial
8	Tamoxifen Citrate Tablets IP 10 mg	10's
9	Tamoxifen Citrate Tablets IP 20 mg	10's
10	Trastuzumab Injection 440 mg With Wfi	1's
11	Methotrexate Tablets IP 7.5 mg	10's
12	Megestrol Acetate Tablets IP 40mg	10's
13	Anastrozole Tablets IP 1mg	10's
14	Bicalutamide Tablets IP 50mg	10's
15	Bortezomib Injection IP 3.5 mg	Vial
16	Dacarbazine Injection 200mg	VIAL
17	DaunorubicinHCl Injection 20mg	vial
18	ImatinibMesylate Tablets IP 400mg	10's
19	Lenalidomide Capsules 10mg	10's
20	Letrozole Tablets IP 2.5mg	10's
21	Leuprolide Acetate Injections 3.75mg	1's
22	Oxaliplatin Injections IP 50mg	Vial
23	Paclitaxel Injection IP 100mg (6mg/ml)	Vial
24	5-Flurouracil Inj. 500mg	10 ml
25	Carboplatin Injection 150mg	15 ml Vial
26	Carboplatin Injection IP 450mg	45 ml Vial
27	Cyclophosphamide 500 mg injection	VIAL
28	Hydroxyurea Capsules IP 500mg	10's
29	Ifosfamide Inj. 1GM	VIAL
30	Docetaxel Injection IP 80 mg	VIAL

31	Docetaxel Injection IP 120 mg	VIAL
32	Erlotinib Tablets IP 150 mg	10's Bottle
33	Gefitinib Tablets IP 250 mg	10's
34	Pemetrexed Injection IP 100 mg	VIAL
35	Pemetrexed Injection IP 500 mg	VIAL
36	Temozolomide Capsules IP 100mg	5's in Bottle
37	Temozolomide Capsules IP 250 mg	5's
38	Capecitabine Tablets IP 500mg	10's
39	Etoposide Capsules IP 50 mg	8's
40	Methotrexate Tablets IP 2.5mg	10's
41	Methotrexate Tablets IP 10mg	10's
42	Methotrexate Tablets IP 5mg	10's
43	Dasatinib 50mg Tablets	60's Bottle
44	Lenalidomide Capsules 25mg	30's in PET bottle in Mono Carton
45	Lenalidomide Capsules 5mg	30's in PET bottle in Mono Carton
46	Thalidomide Capsules 100mg	10's
47	Thalidomide Capsules 50mg	10's
48	Lapatinib Tablets IP 250mg	30's Bottle
49	Bortezomib 2mg powder for Injection	Vial with WFI
50	Dasatinib Tablets 20mg	60's Bottle in Monopack
51	Dasatinib Tablets 50mg	60's Bottle in Monopack
52	Dasatinib Tablets 70mg	60's Bottle in Monopack
53	Methotrexate Tablets IP 15mg	10's
54	Methotrexate Tablets IP 20mg	10's
55	Pazopanib Tablets 200mg	30's bottle in Monopack
56	Pazopanib Tablets 400mg	30's bottle in Monopack

57	Sorafenib Tablets 200mg	30's bottle in Monopack
58	Sunitinib Capsules 12.5mg	10's
59	Sunitinib Capsules 25mg	10's
60	Temozolomide Capsules IP 20mg	10's
61	Thalidomide Capsules 200mg	10's
62	Rituximab 100mg/10ml Injection	10ml vial
63	Rituximab 500mg/50ml Injection	50ml vial
64	Abiraterone Acetate Tablets 250mg	120's bottle
65	Nintedanib Soft gelatin Capsules 150mg	10's
66	Pomalidomide 2mg Capsules	21's in bottle
67	Bortezomib 2.5mg powder for Injection	Vial with WFI
68	Crizotinib Capsules 250mg	60's Bottle in Monopack
69	Nintedanib Soft Gelatin Capsules 100mg	10's
70	Methotrexate Injection IP 25mg/ml	1ml Ampoule
71	Methotrexate Injection IP 50mg/2ml	2ml Ampoule
72	Panitumumab 100mg Infusion	5ml Vial
73	Panitumumab 400mg Infusion	20ml Vial
74	Cabozantinib Tablets 20 mg	30's bottle
75	Cabozantinib Tablets 40 mg	30's bottle

76	Cabozantinib Tablets 60 mg	30's bottle
77	Octreotide long acting release Injection 20mg (Lyophilised)	Vial
78	Octreotide long acting release Injection 30mg (Lyophilised)	Vial
79	Octreotide injection 50 mcg	1ml Ampoule
80	Octreotide injection 100mcg	1ml Ampoule
81	Olaparib Tablet 100 mg	30's in bottle
82	Olaparib Tablet 150 mg	30's in bottle
83	Vincristine Injection 1mg	1ml Vial